Noxopharm Ltd has released a press release.
Noxopharm IONIC Immuno-Oncology Trial Commences
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- NOXCOVID Trial Advances to Final Stage
- Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate
- Company Announcement Regarding Appendix 3Y Disclosures
- Appendix 4D and Half Year Financial Report
- LuPIN Survival Outcome Confirmed by Conference Presentation
Later from Noxopharm
- Veyonda Patent Lodged for Major Septic Shock Opportunity
- Noxopharm Files Septic Shock Treatment Patent for Veyonda®
- Veyonda Showing Potential to Prevent Cytokine Storm
- March Quarterly Activities Report and Appendix 4C
- Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm